Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Entrada Therapeutics Inc ( (TRDA) ) has provided an update.
On January 8, 2026, Entrada Therapeutics reported significant 2025–early 2026 progress across its RNA-based pipeline for neuromuscular and ocular diseases, including completion of Cohort 1 dosing in the global Phase 1/2 MAD ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy (DMD), transition to the open-label Phase 2 portion, and receipt of Rare Pediatric Disease Designation from the U.S. FDA in December 2025. The company has initiated dosing in the Phase 1/2 MAD ELEVATE-45-201 trial of ENTR-601-45, secured U.K. authorization to start a Phase 1/2 MAD study of ENTR-601-50 in DMD patients amenable to exon 50 skipping, plans regulatory filings for ENTR-601-51 in 2026, and continues to support Vertex’s ongoing global Phase 1/2 trial of VX-670 in myotonic dystrophy type 1, targeting completion of the MAD portion’s enrollment and dosing in the first half of 2026. Entrada also expanded into ophthalmology by selecting ENTR-801 in December 2025 as its first ocular clinical candidate for Usher syndrome type 2A, supported by robust preclinical data, and indicated that around 15,000 US and European patients may be addressable by exon 13 skipping; coupled with a reported cash runway into the third quarter of 2027 and a high-profile investor presentation scheduled for January 14, 2026 at the J.P. Morgan Healthcare Conference, these developments underscore the company’s intent to solidify its position as a leading player in RNA-based therapies for high-unmet-need genetic diseases.
The most recent analyst rating on (TRDA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.
Spark’s Take on TRDA Stock
According to Spark, TipRanks’ AI Analyst, TRDA is a Neutral.
Entrada Therapeutics Inc’s overall stock score is primarily influenced by its financial challenges, including declining revenues and persistent losses. Despite these issues, the stock exhibits strong technical momentum, which boosts its score. However, valuation concerns due to negative earnings and lack of dividends weigh down the overall assessment.
To see Spark’s full report on TRDA stock, click here.
More about Entrada Therapeutics Inc
Entrada Therapeutics Inc. is a Boston-based clinical-stage biopharmaceutical company developing RNA- and protein-based medicines that target intracellular pathways previously considered inaccessible, using its proprietary Endosomal Escape Vehicle (EEV) delivery platform. The company focuses on neuromuscular and ocular diseases, with lead oligonucleotide programs for Duchenne muscular dystrophy (DMD) patients amenable to exon 44, 45, 50 and 51 skipping, as well as partnered development of VX-670 for myotonic dystrophy type 1 and newly advancing ocular candidates for inherited retinal disorders such as Usher syndrome type 2A.
Average Trading Volume: 225,469
Technical Sentiment Signal: Buy
Current Market Cap: $385.2M
See more insights into TRDA stock on TipRanks’ Stock Analysis page.